comparemela.com

Latest Breaking News On - Global oncology - Page 6 : comparemela.com

EMA Validates MAA for Repotrectinib in ROS1+ NSCLC and NTRK+ Solid Tumors

The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.

Traveling Safely With Cancer: Tips & Precautions

Explore safe travel tips for cancer patients, including when not to travel, potential risks, and how to prepare for a trip. Learn about medical travel agencies and travel health specialists.

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

CHMP Recommends Adagrasib for Pretreated KRAS G12C+ Advanced NSCLC

After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.